Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study

Zacks12-12

Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490338438?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707","is_english":true,"pubTime":"2024-12-12 21:39","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490338438","market":"us","top_or_hot":-1,"title":"Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study","media":"Zacks","content":"<div>\n<p>Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/eli-lilly-reports-positive-data-133900351.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Eli Lilly Reports Positive Data From Late-Stage Breast Cancer Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEli Lilly Reports Positive Data From Late-Stage Breast Cancer Study\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 21:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/eli-lilly-reports-positive-data-133900351.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease ...</p>\n\n<a href=\"https://finance.yahoo.com/news/eli-lilly-reports-positive-data-133900351.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2602419157.SGD","symbol_name":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/eli-lilly-reports-positive-data-133900351.html","article_id":"2490338438","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/qi8AmKRuXk4zL7mGsiR5yg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/60c096e1e24bb285c41a58d325d8d707"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490338438","pubTimestamp":1734010740,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer .The EMBER-3 study enrolled patients with estrogen receptor -positive, HER2-negative ABC whose disease progressed during or following an aromatase inhibitor  therapy, with or without a CDK 4/6 inhibitor. These patients were then randomized into three equal groups to receive imlunestrant monotherapy, a combination of imlunestrant and Lilly’s blockbuster breast cancer drug Verzenio  or standard of care  endocrine therapy .Treatment with imlunestrant monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival  compared to SOC ET in patients with ESR1 mutations. Data from the study showed that the drug significantly reduced the risk of progress","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PFS":"Provident Financial Services Inc","SG9999014906.USD":"大华全球优质成长基金Acc USD","SG9999001176.USD":"United Global Healthcare Acc USD","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","BK4097":"系统软件","SG9999018865.SGD":"United Global Quality Growth Fd Cl Dist SGD-H","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","OS":"Onestream Inc","ET":"Energy Transfer LP","LU0385154629.USD":"贝莱德营养科学基金A2","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","LU1127390331.HKD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"A\" (HKD) ACC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","SSI":"Stage Stores Inc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","BK4532":"文艺复兴科技持仓","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","BK4590":"PTP","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","NVO":"诺和诺德","LU0097036916.USD":"贝莱德美国增长A2 USD","BK4211":"区域性银行","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LLY":"礼来","AZN":"阿斯利康","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","EBC":"Eastern Bankshares Inc","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC"},"translate_title":"礼来公司报告晚期乳腺癌研究的积极数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ET":1,"LLY":1,"NVO":1,"OS":1,"PFS":1,"EBC":1,"AZN":1,"SSI":1},"content_text":"Eli Lilly LLY announced results from the phase III EMBER-3 study, which showed that treatment with its orally administered investigational drug imlunestrant significantly reduced the risk of disease progression or death in certain patients with advanced breast cancer (ABC).\nThe EMBER-3 study enrolled patients with estrogen receptor (ER)-positive, HER2-negative ABC whose disease progressed during or following an aromatase inhibitor (AI) therapy, with or without a CDK 4/6 inhibitor. These patients were then randomized into three equal groups to receive imlunestrant monotherapy, a combination of imlunestrant and Lilly’s blockbuster breast cancer drug Verzenio (abemaciclib) or standard of care (SoC) endocrine therapy (ET).\nMore on LLY’s EMBER-3 Study Results\nTreatment with imlunestrant monotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS) compared to SOC ET in patients with ESR1 mutations. Data from the study showed that the drug significantly reduced the risk of progression or death by 38% compared to those who received SOC ET in patients with ESR1 mutations.\nHowever, imlunestrant alone did not show a statistically significant PFS benefit in the larger group that included all patients who had received the drug regardless of ESR1 mutations when compared to SoC ET.\nTreatment with the imlunestrant-Verzenio combination also demonstrated a statistically significant and clinically meaningful improvement in PFS in all patients compared to imlunestrant monotherapy. Data from the study showed that the combination significantly reduced the risk of progression or death by 43% compared to those who received imlunestrant alone.\nPer Lilly, the above results demonstrate imlunestrant’s potential as a new oral endocrine therapy option for patients. Management continues to assess the secondary endpoint of overall survival (OS), which at the time of the above analysis is yet to mature.\nLLY Stock Performance\nYear to date, Eli Lilly’s shares have surged 36.6% compared with the industry’s 7.7% rise.\nImage Source: Zacks Investment Research\nVerzenio — A Key Top-line Driver for LLY\nAn orally administered CDK4/6 inhibitor, Verzenio is approved in more than 90 countries, including the United States and the European Union (marketed as Verzenios), for use in certain patients with HR-positive, HER2-negative breast cancers in the adjuvant and advanced or metastatic setting.\nIn the first nine months of 2024, the drug added sales worth $3.8 billion to Lilly’s top line, up 38% year over year. Sales of this drug have been rising, driven by strong demand in the early breast cancer (EBC) indication.\nOther Therapies Rivalling LLY’s Imlunestrant\nImlunestrant is a brain-penetrant selective estrogen receptor degrader (SERD) that offers continuous ER inhibition, including in ESR1-mutant cancers.\nIf approved, the drug will face stiff competition from Orserdu, which was approved by the FDA last year as the first orally administered SERD. The drug is marketed by Italy-based Menarini Group.\nAstraZeneca AZN is also developing its oral SERD drug, camizestrant, in multiple late-stage studies as both monotherapy and combination with CDK4/6 inhibitors across different breast cancer settings. AZN also markets Faslodex, a SERD drug that is approved for administration via an injection.\nWe remind investors that Lilly’s Verzenio is approved in combination with AstraZeneca’s Faslodex to treat certain patients with advanced/metastatic breast cancer.\nLLY Partners With Ro to Expand Obesity Drug Access\nIn a separate press release, telehealth firm Ro announced that it will offer single-dose vials of Eli Lilly's popular obesity drug Zepbound on its platform. This makes it the first alternative platform to offer the lower-cost version outside Lilly's direct-to-consumer website, LillyDirect.\nThe vials will be offered as a treatment option with an on-label prescription from a Ro-affiliated provider through an integration with the LillyDirect’s self-pay pharmacy channel.\nLilly’s intent behind this launch seems clear – to ensure a ‘broader availability’ of Zepbound. The single-dose vials of the drug were launched by the company in August to meet the high demand for the drug. These vials are sold without an autoinjector, making it easier and less time-consuming to manufacture them and improve supply. Patients will require a syringe to inject themselves.\nRo also offers to fill prescriptions for Novo Nordisk’s NVO Wegovy, a rival to Lilly’s Zepbound.\n\nEli Lilly and Company Price\n\nEli Lilly and Company price | Eli Lilly and Company Quote\n\nLLY’s Zacks Rank\nEli Lilly currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nAstraZeneca PLC (AZN) : Free Stock Analysis Report\nNovo Nordisk A/S (NVO) : Free Stock Analysis Report\nEli Lilly and Company (LLY) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490338438"}